Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]ER176
- Development stage
- Phase 3
- Lead developer
- National Institute of Mental Health
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[11C]ER176 is a Carbon-11 labeled positron emission tomography (PET) radioligand developed by the National Institute of Mental Health (NIMH) for imaging the 18-kDa translocator protein (TSPO). TSPO is a protein located on the outer mitochondrial membrane that is highly expressed in activated macrophages and microglia, serving as a sensitive biomarker for both neuroinflammation and peripheral inflammation. [11C]ER176 is a quinazoline derivative designed to overcome the limitations of earlier TSPO tracers, such as PK11195 and PBR28, by providing improved binding characteristics and showing reduced sensitivity to the rs6971 genetic polymorphism that typically causes high variability in binding affinity among different individuals. It is currently being evaluated in Phase 1 clinical studies as an imaging biomarker to quantify inflammation in musculoskeletal conditions, including rheumatoid arthritis, idiopathic inflammatory myopathy, and axial spondyloarthritis.
- Other names
- 11C-ER176
02
Targets
TSPO (Translocator Protein (18 kDa))
Beyond the preview
Go deeper on [11C]ER176.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [11C]ER176.